Abstract
Although the adjuvant tamoxifen benefit/risk rate is unquestionable in breast cancer treatment, the increase of endometrial cancer in chemoprevention is about to be a real problem. In the studies currently published metrorragia in the main signal. Levonogestrel intra-uterine device has not proved its efficacy for the decrease of this risk.
MeSH terms
-
Antineoplastic Agents, Hormonal / adverse effects*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Breast Neoplasms / drug therapy
-
Endometrial Neoplasms / chemically induced
-
Endometrial Neoplasms / prevention & control
-
Endometrium / drug effects*
-
Female
-
Humans
-
Intrauterine Devices, Medicated*
-
Levonorgestrel / administration & dosage*
-
Metrorrhagia / chemically induced
-
Metrorrhagia / prevention & control
-
Tamoxifen / adverse effects*
-
Tamoxifen / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Tamoxifen
-
Levonorgestrel